Clinical trial readout dates for Krystal Biotech Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
The next expected readout is December 2026.
Next readoutDecember 2026in ~1 month
Upcoming readouts41 Phase 3
Market cap$9.9B
Cash & investments$912Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-02
Upcoming readouts
Phase 3KB803
Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa · NCT07016750
Krystal Biotech Inc. reported $912M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). It reported net income of $63M for that quarter.
Recent SEC filings
8-KResults of Operations — earnings, may carry pipeline updates